United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 43,025 shares of the company’s stock in a transaction that occurred on Friday, March 16th. The shares were sold at an average price of $111.11, for a total value of $4,780,507.75. Following the completion of the transaction, the chief executive officer now owns 21,652 shares in the company, valued at approximately $2,405,753.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of United Therapeutics Co. (NASDAQ UTHR) traded up $0.14 during mid-day trading on Friday, reaching $111.14. 575,296 shares of the company’s stock were exchanged, compared to its average volume of 524,486. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.26 and a quick ratio of 3.01. United Therapeutics Co. has a 1-year low of $107.82 and a 1-year high of $152.55. The company has a market cap of $4,799.61, a PE ratio of 11.90 and a beta of 1.32.
United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, February 21st. The biotechnology company reported $3.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.59 by $0.30. United Therapeutics had a net margin of 24.22% and a return on equity of 24.41%. The business had revenue of $464.70 million for the quarter, compared to analysts’ expectations of $420.55 million. During the same quarter in the previous year, the firm posted $4.12 EPS. The business’s revenue for the quarter was up 13.6% compared to the same quarter last year. analysts forecast that United Therapeutics Co. will post 12.46 EPS for the current fiscal year.
Several research firms recently commented on UTHR. ValuEngine downgraded United Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, February 27th. BidaskClub downgraded United Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, February 24th. Barclays reiterated an “underweight” rating and issued a $105.00 price objective (down previously from $115.00) on shares of United Therapeutics in a research note on Thursday, February 22nd. Credit Suisse Group reiterated an “underperform” rating and issued a $115.00 price objective (down previously from $120.00) on shares of United Therapeutics in a research note on Thursday, February 22nd. Finally, Zacks Investment Research upgraded United Therapeutics from a “hold” rating to a “buy” rating and set a $160.00 price objective on the stock in a research note on Monday, January 15th. Five analysts have rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $135.20.
A number of hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC raised its holdings in United Therapeutics by 14.9% during the 4th quarter. Renaissance Technologies LLC now owns 1,462,378 shares of the biotechnology company’s stock valued at $216,359,000 after acquiring an additional 189,378 shares during the period. Acadian Asset Management LLC increased its holdings in shares of United Therapeutics by 2.4% in the fourth quarter. Acadian Asset Management LLC now owns 1,121,068 shares of the biotechnology company’s stock worth $165,861,000 after purchasing an additional 26,122 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of United Therapeutics by 9.8% in the third quarter. Dimensional Fund Advisors LP now owns 798,093 shares of the biotechnology company’s stock worth $93,531,000 after purchasing an additional 71,333 shares during the period. Wells Fargo & Company MN increased its holdings in shares of United Therapeutics by 2.0% in the fourth quarter. Wells Fargo & Company MN now owns 744,312 shares of the biotechnology company’s stock worth $110,120,000 after purchasing an additional 14,593 shares during the period. Finally, APG Asset Management N.V. increased its holdings in shares of United Therapeutics by 8.3% in the fourth quarter. APG Asset Management N.V. now owns 705,900 shares of the biotechnology company’s stock worth $86,974,000 after purchasing an additional 53,900 shares during the period.
WARNING: This story was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://ledgergazette.com/2018/03/17/united-therapeutics-co-uthr-ceo-martine-a-rothblatt-sells-43025-shares.html.
United Therapeutics Company Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.